Charles River Labs Extends CEO’s Term Amid Shareholder Meeting

Charles River Labs ( (CRL) ) has provided an update.

On May 20, 2025, Charles River Laboratories extended the employment term of its CEO, James C. Foster, by an additional year, maintaining existing terms. During the same day, the company held its Annual Meeting of Shareholders, electing seven directors, appointing four new board members, and approving executive compensation and auditor appointments, while rejecting a proposal from PETA regarding non-human primate reports.

The most recent analyst rating on (CRL) stock is a Hold with a $235.00 price target. To see the full list of analyst forecasts on Charles River Labs stock, see the CRL Stock Forecast page.

Spark’s Take on CRL Stock

According to Spark, TipRanks’ AI Analyst, CRL is a Neutral.

Charles River Labs’ overall stock score reflects robust cash flow and strategic leadership changes, countered by valuation concerns and profitability challenges. While the earnings call and corporate events provide optimism, revenue and profitability declines weigh on the stock’s outlook.

To see Spark’s full report on CRL stock, click here.

More about Charles River Labs

Charles River Laboratories International, Inc. operates in the life sciences industry, providing essential products and services for drug discovery and development. The company focuses on offering preclinical and clinical laboratory services to pharmaceutical, biotechnology, and other life sciences organizations.

Average Trading Volume: 1,772,068

Technical Sentiment Signal: Sell

Current Market Cap: $6.66B

For detailed information about CRL stock, go to TipRanks’ Stock Analysis page.